FY2028 EPS Estimates for argenx Increased by Leerink Partnrs

argenx SE (NASDAQ:ARGX) – Stock analysts at Leerink Partnrs lifted their FY2028 EPS estimates for argenx in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of $34.69 for the year, up from their previous estimate of $34.23. The consensus estimate for argenx’s current full-year earnings is $2.78 per share. Leerink Partnrs also issued estimates for argenx’s FY2029 earnings at $41.83 EPS.

Other analysts have also issued research reports about the company. Robert W. Baird lowered argenx from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $515.00 to $650.00 in a report on Friday, November 1st. Citigroup increased their target price on shares of argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. William Blair raised shares of argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. HC Wainwright reissued a “buy” rating and issued a $717.00 price objective (up from $670.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, Wolfe Research upgraded shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price on the stock in a research note on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $658.39.

argenx Price Performance

NASDAQ:ARGX opened at $646.64 on Thursday. argenx has a one year low of $349.86 and a one year high of $678.21. The business has a fifty day moving average price of $636.51 and a 200-day moving average price of $574.93. The firm has a market capitalization of $39.29 billion, a price-to-earnings ratio of -734.82 and a beta of 0.58.

Institutional Trading of argenx

Hedge funds have recently modified their holdings of the company. Whipplewood Advisors LLC purchased a new position in shares of argenx in the 4th quarter worth $37,000. Global Retirement Partners LLC lifted its holdings in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after acquiring an additional 48 shares during the last quarter. Jones Financial Companies Lllp grew its position in argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after acquiring an additional 61 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in argenx during the fourth quarter worth approximately $66,000. Finally, Nkcfo LLC purchased a new stake in argenx during the fourth quarter valued at approximately $68,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.